Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 10/10/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Murray J. Favus

Wrong Dr. Murray J. Favus?

Director of the Bone Program

University of Chicago
1111 E. 60th St.
Chicago, Illinois 60637
United States

Company Description: Founded by oil magnate John D. Rockefeller, the University of Chicago is a private, nondenominational institution of higher learning. Scientists at the University...   more
Background

Employment History

  • Director of the Clinical Research Center
    University of Chicago
  • Director of the Bone Program and the Clinical Research Center
    University of Chicago Medical Center
  • Professor of Medicine
    Univ Chicago School of Med
  • Professor of Medicine, Director of the Bone Program
    University of Chicago School of Medicine
  • Director of Bone Program
    University of Chicago Medicine

Board Memberships and Affiliations

Education

  • M.D.
  • MD
40 Total References
Web References
Osteoporosis Recs Urge Screening for More Women
www.breastcancer.org, 29 Aug 2011 [cached]
Also in an e-mail, Murray Favus, MD, director of the bone program at the University of Chicago, said that the lack of a plan for assessing fracture risk in men is a major problem with the guidelines.
"It is time to recognize that men will continue to be neglected until reimbursement for bone-density scans is in place," he wrote, "and a first step is inclusion of management of men in the guideline."
Infection Control Today - 03/2004: Handwashing and Cross Contamination
www.infectioncontroltoday.com, 27 Feb 2004 [cached]
"It's a standard practice, but with busy schedules, complying is not always easy for some professionals," says Dr. Murray Favus, who was director of the Clinical Research Center at the University of Chicago for the last 19 years.
As an example, he describes the process of making patient rounds along with a small team of interns, residents and students.
"Typically, as many as four of us might have patient contact, shifting a person's position in bed so we can examine his or her condition or change a dressing.A sink, soap and paper towels are in or near every room, but the cleaning process slows us down.If four people have to scrub down after seeing 15 patients in the morning, that's 60 handwashings."
Favus says everyone wants to follow policy, but no one wants to slow the team's progress.Not every washing is thorough.
Doctors and staff in the intensive care unit must be even more diligent, he says, pointing out that the sickest people require more frequent monitoring.
...
Favus sees value in having automatic flushers in washrooms used by patients."It's one less step for a weak patient," he says.
In an email to Reuters Health, ...
www.caring4womenshealth.com, 18 Feb 2011 [cached]
In an email to Reuters Health, Dr. Murray Favus, who directs the bone program at the University of Chicago Medical Center, said the new findings might ease concerns about the drugs.
Only about one in 100,000 people taking bone drugs actually develop osteonecrosis of the jaw, he said, and the atypical fractures linked to the drugs are also very uncommon he said.
"The concern about complications or just not being committed to the medication has led many patients to stop oral bisphosphonate therapy," he said.
Endotext.com - Diseases Of Bone And Calcium Metabolism, Contributors
www.endotext.org, 27 July 2006 [cached]
Murray Favus, MD Director, Bone Program: Director, Clinical Research Center University of Chicago Medical Center,-MC5100, 5841 South Maryland Ave, Chicago, IL 60637
Optimism on Osteoporosis: Research and Treatment
www.todaysgeriatricmedicine.com, 30 June 2009 [cached]
"The awareness of it really came about 15 to 20 years ago," says Murray Favus, MD, director of the Bone Program and the Clinical Research Center at the University of Chicago Medical Center, who holds appointments in endocrinology and nephrology.
...
"It's certainly the frontline drug," Favus says.
...
"We recommend people should keep good oral health, but they don't need to stay away from the drug," Favus says.
Other bisphosphonates include risedronic acid (Actonel), also a widely used oral drug taken monthly, and ibandronic acid (Boniva), which is taken once per month or four times per year intravenously.
Zoledronic acid (Reclast) is given once per year intravenously and can last for 12 months following one infusion. Originally developed in 2001 to treat bone cancer, it was thought for years to be an effective treatment for osteoporosis. Approved by the FDA in 2007, the drug can be administered intravenously in only 15 minutes, is well tolerated, and "reduces hip and spine fractures as well as anything available on the market now," according to Favus. Individuals on Reclast do not need to take anything other than calcium and vitamin D supplements, he adds, which are the building blocks for all these treatments.
...
"SERMs are important options, especially for those who may not respond to bisphosphonates," Favus says.
Also referred to as estrogen agonists/antagonists, the drugs work like estrogen on the bone, while at other sites, such as the breast, the drug acts as an antiestrogen. "This means they don't stimulate breast tissue nor do they stimulate the lining of the uterus. They have even been shown to reduce the rates of new breast cancers," Favus says.
One SERM approved by the FDA in 2007 is raloxifene (Evista). The daily drug, taken orally, has been shown in clinical studies to reduce spinal fractures, but data do not support a reduction in hip fractures. "That's a concern, and so the doctor has to look carefully at the needs of the individual patient in terms of selecting a drug," Favus says.
...
But most important to Favus "is that we may soon have another very effective drug."
...
Murray Favus, MD, of the University of Chicago Medical Center, would like to see strontium ranelate given a trial in the United States but doubts it will happen because of expensive trial costs that could lead to companies sharing profits.
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304